We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current CMOPF market cap is 1.3B. The company's latest EPS is EUR -0.3033 and P/E is -418.40.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 63.25M | 66.8M | 65.89M | 103.99M | 94.23M |
| Operating Income | -17.37M | 1.96M | 28.3M | 28.06M | 6.15M |
| Net Income | -24.42M | -7.9M | 21.67M | 17.23M | -4.93M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 585.16M | 596.16M | 805.56M | 759.59M | 553.98M |
| Total Liabilities | 191.43M | 196.04M | 292.88M | 295.8M | 124.94M |
| Total Equity | 393.73M | 400.13M | 512.68M | 463.79M | 429.04M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -18.85M | 12.99M | 12.61M | 33.23M | 33.62M |
| Investing | -48.69M | 75.45M | 24.86M | 1.69M | 42.3M |
| Financing | -34.46M | -11.88M | -27.25M | -46.13M | -211.27M |
| Market Cap | 1.3B |
| Price to Earnings Ratio | -418.40 |
| Price to Sales Ratio | 21.9 |
| Price to Cash Ratio | 41.04 |
| Price to Book Ratio | 4.81 |
| Dividend Yield | - |
| Shares Outstanding | 16.26M |
| Average Volume (1 week) | 13 |
| Average Volume (1 Month) | 39 |
| 52 Week Change | 90.62% |
| 52 Week High | 80.25 |
| 52 Week Low | 41.50 |
| Spread (Intraday) | 5 (6.23%) |
| Company Name | Cosmo Pharmaceuticals NV (PK) |
| Address |
riverside ii dublin 20020 |
| Website | https://www.cosmopharmaceuticals.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
